Introduction
============

The global figures on tuberculosis (TB) urge for optimized control strategies and efficient allocation of resources to reduce TB mortality and morbidity rates. In 2016, the WHO reported 10.4 million new cases and approximately 1.8 million deaths caused by TB.[@b1-idr-11-2219] A particular concern in TB control is the worldwide emergence of resistant, multidrug-resistant (MDR), and extensively resistant (XDR) *Mycobacterium tuberculosis* complex (MTBC) strains.[@b1-idr-11-2219] M/XDR-TB is considerably more difficult to treat (longer duration, second-line drugs with severe side effects) and has much poorer treatment outcomes.[@b2-idr-11-2219]

Saudi Arabia is classified by the WHO as a moderate TB-burden country;[@b1-idr-11-2219] however, several factors may contribute to TB transmission and the emergence of drug resistance among new cases. The country has a unique geographical location, situated in the heart of three different continents: Africa, Asia, and Europe. As such, it serves as a major migration hub. In addition, the country hosts millions of Islamic pilgrims annually, most of whom arrive from highly TB-endemic regions, and only 60% of the total population are Saudis.[@b3-idr-11-2219] The resulting mobility increases the risk of the introduction and transmission of "imported" M/XDR strains from patients who have not been registered or identified by local TB-control measures.

The first molecular epidemiology study in the country, based on spoligotyping, revealed the presence of the geographically dominating Delhi/CAS genotype among others, such as Latin American Mediterranean (LAM), East African Indian (EAI), Uganda, Ghana, Cameroon, Haarlem, and Beijing, which may reflect transmission from immigrated TB patients.[@b4-idr-11-2219] Recently, Varghese et al applied 24 loci MIRU-VNTR typing for the analysis of drug resistant (mono, poly, and multidrug resistant) MTBC strains, and showed the predominance of Delhi/CAS, EAI, Beijing, Ghana, and Haarlem genotypes. In addition, the study revealed a high cluster rate between local and immigrant population with no association between patient origin and strain genotype.[@b5-idr-11-2219] However, both, spoligotyping and MIRU-VNTR typing have a low discriminatory power to precisely analyze the genetic relationship of MTBC strains as a surrogate marker for the extent of recent patient-to-patient MTBC transmission, especially in high-incidence populations.[@b2-idr-11-2219],[@b6-idr-11-2219],[@b7-idr-11-2219] Here, whole genome sequencing (WGS)-based approaches have a clear advantage by allowing the discrimination of clinical MTBC strains at the highest resolution and simultaneously enabling detailed resistance predictions for, virtually, all drugs.[@b2-idr-11-2219],[@b8-idr-11-2219] More recently, the first national surveillance study conducted on 1,902 MTBC strains revealed an alarming proportion of 4.5% MDR-TB cases in the country.[@b9-idr-11-2219] However, high-resolution data on transmission patterns or molecular drug-resistance profiles using WGS in Saudi Arabia is lacking, which is a critical step to define the underlying epidemiology of MDR-TB and its transmission dynamics with high precision.

To address these questions, we utilized a WGS approach to characterize all MDR-MTBC strains sampled from different provinces of the country between 2015 and 2017. In addition, we included a cohort of non-MDR MTBC strains to point out putative associations between patients infected with MDR and non-MDR MTBC strains, which were also stratified on the basis of their demographic and clinical parameters.

Materials and methods
=====================

Study design
------------

The Mycobacteriology Research Section of King Faisal Specialist Hospital and Research Center maintains a national-level collection of clinical isolates as part of the National TB Surveillance Study during August 2015 to July 2017. The collection of isolates applied the WHO's 100% collection policy during the execution time; thus, a fair and extensive coverage rate was acquired. During the period, 2,156 isolates were collected; 394/2156 were either not successfully cultured or recognized as non-MTBC strains. The remaining 1,762 isolates were subjected to phenotypic drug-susceptibility testing (DST) and mutation-detection via Line Probe Assay (LPA) as an initial screening method. A total of 71 isolates were phenotypically defined as MDR strains and were accordingly considered in the study. Another 134 non-MDR-TB strains were included as background samples to obtain a final sample size of 205 isolates.

Demographic and clinical data were gathered using data collection forms from the provincial laboratories on the basis of national TB codes, and the data were verified at the National TB Registry. The data collection was strictly anonymous and no patient identifiers were used throughout the collection and analysis period. The study has been reviewed and approved by the Office of Research Affairs at King Faisal Specialist Hospital and Research Center, Riyadh, Saudi Arabia.

Laboratory methods and data analysis
------------------------------------

All the isolates were subjected to DST of four first-line drugs (isoniazid, rifampicin, streptomycin, and ethambutol) using the MGIT SIRE kit (Becton Dickinson, USA) as an initial screening method. Genomic DNA was extracted with a standard spin-column technique as per the manufacturer's recommendations (QIAamp DNA mini Kit, Qiagen, Germany). Primary rapid screening of mutations conferring resistance to rifampicin and isoniazid was carried out using the LPA Genotype MTBDR *Plus* (Hain Life Science, Nehren, Germany).

From the extracted genomic DNA, WGS was carried out with Illumina next-generation sequencing technology, using the Nextera XT library preparation kit and the NextSeq-500 sequencing platform as instructed by the manufacturer (Illumina, San Diego, CA, USA). Reads were mapped to the genome of *M. tuberculosis* H37Rv (GenBank ID: NC_000962·3) with the alignment program SARUMAN.[@b10-idr-11-2219] All datasets reached a minimum average coverage depth of 54.8-fold, with at least 98.6% of the reference genome covered by at least one read for all isolates. For variant detection in the mapped reads, we employed minimum thresholds of 10× coverage and 75% allele frequency. Variant positions were then combined, supplementing the joint list with the respective information from the original mappings where necessary. SNP positions with a reliable base call (10× coverage and 75% allele frequency) in at least 95% of the isolates were concatenated to a sequence alignment, excluding SNPs occurring within a window of 12 bp from each other in the same isolate. Genome clusters were defined by grouping all isolates within a maximum distance of five SNPs to the nearest group member -- an empirically defined cutoff for epidemiologically related cases (ie, household contacts).[@b11-idr-11-2219] Polymorphisms in 37 drug-resistance and bacterial fitness-associated target genes were investigated and used to construct molecular drug-resistance profiles of all MDR-MTBC strains ([Table S1](https://doi.org/10.6084/m9.figshare.7159853.v1)). SNPs in 37 resistance-related target genes that were found in at least two isolates of the same MTBC genotype but were not associated to phenotypic resistance were excluded as putative phylogenetic variants (Table S1).

Data analysis was conducted using the software package SPSS version 19.0 (IBM Corporation, Armonk, NY, USA). Pearson's χ2 statistics or Fisher's two-tailed test was used to compare categorical variables. All variables were studied in a univariate logistic regression analysis. In all analyses, 95% CIs and *P*-values were corrected for the definite population of genomic clusters.

Results
=======

Overall, 71 genotypically confirmed MDR-TB and 134 non-MDR-TB cases were enrolled for final data analysis, including the mainly pulmonary specimens (88.3%) and extra-pulmonary specimens (12%; [Table 1](#t1-idr-11-2219){ref-type="table"}). All enrolled isolates were culture-positive and 72% were smear-positive ([Table 1](#t1-idr-11-2219){ref-type="table"}). MTBC strains were derived from 62.9% male and 37.1% female patients; the dominating age groups were 16--29 years (32.2%) and 30--45 years (37.1%). Similar proportions of Saudi and non-Saudi patients were included, mainly originating from the Central (27.3%) and Western provinces (34.1%). On comparing MDR and non-MDR-TB cases in a univariate analysis, we found no differences in the general patient characteristics described earlier. However, MDR-TB patients were more often observed with smear-positive acid-fast bacilli specimens (*P*=0.001), higher treatment-failure rates (*P*=0.002), deportation (*P*=0.006), and patient death (*P*=0.017; [Table 1](#t1-idr-11-2219){ref-type="table"}).

All strains were phylogenetically classified in accordance with a recently reported SNP barcode nomenclature.[@b12-idr-11-2219] Overall, four major MTBC lineages were identified: 32/205 (15.6%) of isolates were assigned to Lineage 1(EAI), 16/205 (7.8%) to Lineage 2 (Beijing), 43/205 (21.0%) to Lineage 3 (Delhi/CAS), 113/205 (55.1%) to Lineage 4 (Euro-American super-lineage), and one isolate was classified as *Mycobacterium bovis* ([Figure 1](#f1-idr-11-2219){ref-type="fig"}, Figure S1). With regard to the MDR-MTBC population structure in particular, we assigned 11/71 (15.5%) isolates to Lineage 1, 11/71 (15.5%) to Lineage 2, 17/71 (23.9%) to Lineage 3, and 32/71 (45.0%) to Lineage 4 ([Table 2](#t2-idr-11-2219){ref-type="table"}).

On a sub-lineage level, the most prevalent MDR-MTBC groups that could be further differentiated by the applied SNP barcode were Lineage 4.2.2 (associated with the TUR genotype; 13/71, 18.3%), Lineage 1.1.2 (associated with the EAI genotype; 10/71, 14.1%), Lineage 2.2.1 (associated with the Beijing genotype; 10/71, 14.1%), and Lineage 4.6.2.2 (associated with the Cameroon genotype; 7/71, 9.9%; [Table 2](#t2-idr-11-2219){ref-type="table"}). Compared to the non-MDR-MTBC strains (n=134), strains belonging to Lineage 2 were enriched in the MDR-TB cohort (*P*=0.006) whereas all other identified lineages and sub-lineages were observed with similar proportions in both datasets ([Table 2](#t2-idr-11-2219){ref-type="table"}).

Primary screening of phenotypically and genotypically confirmed MDR-MTBC strains with LPA identified 43/71 (60.6%) S531L (ie, S450L in the *M. tuberculosis* reference genome, see "Methods" section), 4/71 (5.6%) H526Y (ie, H445Y) and 4/71 (5.6%) D516V (ie, D435V) mutations in the *rpoB* gene, and 20/71 (28.2%) had a missing wild-type band that indicated another rare mutation in the *rpoB* hotspot region (Tables S1 and S2). With regard to isoniazid-resistance-mediating mutations, 59/71 (83.8%) of the MDR-MTBC isolates showed the mutation *katG* S315T, (8/71, 10.3%) *inhA* mutation in Position --15 (C\>T) and four missing wild-type bands for the *katG* gene (Table S2).

Using WGS, we analyzed insertions, deletions, and SNPs in 37 target genes associated with bacterial fitness and antibiotic resistance. Isoniazid resistance was dominant with the mutation (S315T, 61/71, 85.9%) in *katG* gene. The second common mutation was found in the *inhA* gene (--15 C\>T*,* 8/71 (11.3%; Table S2). Rifampicin resistance was associated with S450L mutation (43/71, 60.6%) followed by H445Y (9/71, 12.7%) of the *rpoB* gene. All strains with undefined mutations in the *rpoB* gene on LPA have mutations at S450W, L452P, L430P, H445R, H544N, and S428G codon positions (Tables S1 and S2).

We analyzed the *rpsL* and *rrs* genes for the mutations conferring streptomycin resistance. The K43R mutation in the *rpsL* gene was found to be the most common mutation (16/71, 22.5%) followed by the 514 A\>C mutation in the *rrs* gene (12/71, 16.9%). Ethambutol-resistant isolates were mainly associated with the mutation *embB* M306V (28/71, 39.4%; Table S2). Furthermore, we identified variants in the upstream region of the gene *pncA,* associated with pyrazinamide resistance, as well as non-synonymous and frame-shift mutations in 52.1% (37/71) of isolates. Overall, 22.5% (16/71) of MDR-MTBC isolates were identified with molecular resistance markers to all five first-line drugs; 5/71 (7.0%) of the MDR-MTBC strains were found with a fluoroquinolone-resistance-mediating mutation (ie, *gyrA* A90V and *gyrA* D94G, respectively) and were defined accordingly as pre-XDR (Table S2). Overall 18/205 isolates (including 13 MDR-MTBC isolates) were observed with prothionamide-and ethionamide-resistance-mediating mutations -- that is, *fabG1/inhA* --15 c/t, *ethA* 672 *insG*, and *ethA* 377 delT (Tables S1 and S2). No resistance marker was identified for second-line injectable drugs or WHO Group Five anti-TB drugs (ie, bedaquiline, delamanid, clofazimine, linezolid, and paraminosalicylic acid). Among 47/71 (66.2%) MDR-MTBC isolates, we identified putative compensatory mutations in the RNA-polymerase genes *rpoA* (1/71; 1.4%)*, rpoB* (32/71; 45.1%), and *rpoC* (23/71; 32.4%). The mutation in the *rpoC* gene was found to dominate (17/23, 73.9%) among isolates as was the S450L mutation of the *rpoB* gene (Table S2).

In order to determine molecular strain clusters indicative of recent chains of MDR-MTBC transmission (within the last 3 years), we defined groups of at least two strains that had a maximum distance of five SNPs to at least one other group member. This threshold was recently shown to be a reliable indicator to identify transmission among household contacts in the UK.[@b11-idr-11-2219] Overall, 48/71 (67.6%) MDR-MTBC isolates were assigned into one of 14 molecular clusters, each comprising two to six patients ([Figure 1](#f1-idr-11-2219){ref-type="fig"}, [Table 3](#t3-idr-11-2219){ref-type="table"}). In contrast, non-MDR strains showed a clustering rate of only 30.6%. Individual MDR-MTBC strains within genomic clusters each presented with identical resistance-conferring mutations in the genes *katG* or *inhA*, and *rpoB* mediating a MDR phenotype ([Table 3](#t3-idr-11-2219){ref-type="table"} and S1). In addition, 29 MDR-TB patients in eight different transmission networks were infected with strains showing cluster-specific *pncA* mutations associated with pyrazinamide resistance -- again, pointing toward ongoing patient-to-patient transmission. However, molecular markers associated with second-line injectable drug resistance were identical only in one cluster.

Demographic data from patients involved in the 14 suggested transmission networks revealed five clusters with only Saudi nationals and one cluster with only non-Saudi nationals. The remaining eight clusters comprised both Saudi and non-Saudi nationals. Ten out of the 14 clusters were linked to a single city, with the remaining four clusters linked to two cities. There was no significant difference in the MDR-MTBC cluster rate on comparing patient origin -- Saudi nationals (57.1%) and non-Saudi nationals (41.2%; *P*=0.629; [Table 4](#t4-idr-11-2219){ref-type="table"}). However, lack of proper social information restricts further analysis of epidemiological associations among the MDR-TB patients ([Table 4](#t4-idr-11-2219){ref-type="table"}). The two major clusters comprised MTBC strains belonging to the Cameroon sub-lineage (4.6.2.2; six cases) and the Beijing lineage (2.2.1; five cases), and included both Saudi and non-Saudi nationals ([Table 3](#t3-idr-11-2219){ref-type="table"}).The following mutations were shared among all strains from the Cameroon genotype cluster (*katG* S315T, *rpoB* S450L, *Rvnr01 514A\>C*, *embB* M306V, and *pncA* T76P). Strains from the Beijing genotype cluster shared the mutations *katG* S315T, *rpoB* S450L, *rpsL* K43R, *embB* M306V, and *pncA* T47I. Overall, 12/14 (85.7%) of the clusters were observed with identical resistance-conferring mutations ([Table 3](#t3-idr-11-2219){ref-type="table"}).

Analysis on confounding factors for MDR-TB clustering showed no statistically significant association with other variables tested, except for the treatment history. Clustered MDR-TB cases were more likely to be new cases (*P*\<0·001), confirming the cluster-definition threshold of five SNPs as an indicator for patient-to-patient transmission ([Table 4](#t4-idr-11-2219){ref-type="table"}).

Discussion
==========

To the best of our knowledge, this is the first study elucidating the transmission dynamics of MDR-MTBC strains using a WGS approach in Saudi Arabia -- a country challenged by high immigration rates. Alarmingly, high cluster rates (67.6%) were determined among the MDR-MTBC strains, leading to a total of 14 putative recent transmission chains. Together with the fact that MDR-TB was not associated with patient origin, this points to ongoing, endemic transmission of MDR-TB within Saudi Arabia. This is particularly important as several clustered strains have already acquired resistance-conferring mutations against all first-line drugs. At the same time, genomic markers for second-line drug resistance are still rare among our study cohort, urging for improved TB-control measures for complete resistance detection and tailored therapy.

An association of MDR-TB with recent transmission has been collectively reported from different geographical settings.[@b13-idr-11-2219]--[@b15-idr-11-2219] Moreover, our findings are in concordance with high rates of MDR-MTBC transmission (45.1%) in countries such as Ethiopia.[@b15-idr-11-2219] Other intermediate TB-burden countries, such as Iran, Iraq, and Turkey reported lower rates of transmission, ranging from 24% to 35.9%, based on classical genotyping methods.[@b14-idr-11-2219],[@b16-idr-11-2219],[@b17-idr-11-2219] Nevertheless, the different methodological approaches employed herein -- compared with studies conducted in nearby regions -- make the process of contextualizing transmission dynamics very challenging. However, strikingly, our data suggest that, transmission of full first-line-resistant MTBC strains leading to extended primary MDR-TB cases is a major factor for the emergence of MDR-TB in Saudi Arabia. This has been further evidenced by identical resistance-conferring mutations in *katG*, *inhA*, *rpoB*, and *pncA* in clustered strains. Thus, transmission chains must be effectively interrupted by proper case finding (beyond conventional contact-tracing), isolation of MDR-TB cases until they are negative, and comprehensive diagnosis to allow for prompt and effective treatment. The latter are critical to significantly decrease the incidence of MDR-TB and avert the emergence of XDR-TB in Saudi Arabia.

A slightly increased cluster rate was evident among Saudi nationals (62.5%) compared to non-Saudi cases. Of the total clusters, 13 had Saudi cases whereas non-Saudis were represented in only nine clusters. There were four clusters exclusively composed of Saudi nationals, whereas only one cluster was exclusively composed of non-Saudi cases. Interestingly, eight clusters contained both local and foreign patients, which corroborate findings from previous studies;[@b5-idr-11-2219] 71.4% of the clusters were found limited to a single city, which supports the possibility of an active ongoing transmission in the local area. However, no statistical evidence has been observed in the geographical origin (province of residence) of patients and strain clusters.

Among the MDR-TB cases found as part of any cluster, only 29.2% of the patients received a full course of therapy, whereas 30.4% patients received therapy among non-clustered cases. The majority of the MDR-TB cases found in clusters had an "unknown" status without follow-up visits, according to the medical records. Thus, Saudi Arabia is still far (62%) from the WHO's MDR-TB treatment-success target (85%). In addition, several previous studies showed a large scale non-compliance of treatment among Saudi nationals in particular.[@b18-idr-11-2219],[@b19-idr-11-2219] Unsuccessful treatment is, therefore, another likely factor for the ongoing transmission of MDR-TB strains.

As expected from the high immigration rate reported in Saudi Arabia, a high phylogenetic diversity of MTBC strains was identified, unlike what has been reported elsewhere.[@b20-idr-11-2219] Besides Lineage 3, MTBC strains that are associated with a South Asian evolutionary origin, and which are also frequently isolated from TB patients in East Africa and the Middle East, we found 55% of all patients being infected with Lineage 4 strains. Strains of the TUR/4.2.2 sub-lineage are most prevalent, followed by strains of the Haarlem/4.1.2.1, and Cameroon/4.6.2.2 lineages. Although Haarlem is one of the globally widespread sub-lineages, the sub-lineages Cameroon and TUR are geographically restricted and have been identified mainly in Asia and Africa, highlighting the impact of high immigration rates from these regions into Saudi Arabia.[@b21-idr-11-2219] In fact, the large clusters of Cameroon and TUR strains identified in our study included non-Saudi nationals, particularly of African (Nigeria) and Middle Eastern (Syria) origin. Similarly, Lineage 3 is frequently identified in Asia and Africa and has been previously reported in Saudi Arabia and Oman with dominating rates.[@b22-idr-11-2219],[@b23-idr-11-2219] The high influx of immigrants coming from Asia and Africa is well reflected by the highly diverse patient population in the study (Figure S1). This might explain the predominance of these sub-lineages in our settings. Strains of lineages 1 and 2, on the other hand, accounted for less than 10% of the investigated strains in this study. This is in contrast to studies in Russia and China, which reported a dominance of Beijing strains and have elucidated an association between Lineage 2 strains and drug resistance.[@b24-idr-11-2219],[@b25-idr-11-2219] In addition, four strains from Saudi patients belonging to Lineage 4 failed to be identified to the sub-lineage level in this study. This might be attributed to a small "blind spot" in the employed SNP-based algorithm,[@b12-idr-11-2219] potentially representing minor novel sub-lineages. Analysis on mutations conferring resistance to isoniazid and rifampicin showed a clear domination of well-established mutations in the *katG* codon 315 and the *rpoB* hotspot region in concordance with previous Saudi Arabian studies by Varghese et al.[@b13-idr-11-2219],[@b26-idr-11-2219] However, there were six other mutations in the *rpoB* hotspot region and one mutation in *katG* which have never been reported in the country before. Likewise, we have identified variants in the upstream region of the gene *pncA* as well as non-synonymous and frame-shift mutations that are associated with pyrazinamide resistance in 22.4% of the isolates. Similar to our results, many studies have reported a variety of scattered and variable set of pyrazinamide resistance-conferring mutations.[@b27-idr-11-2219],[@b28-idr-11-2219] Of note, pyrazinamide is not part of the routine first-line therapy in Saudi Arabia and phenotypic DST is not applied. Thus, our WGS results suggest that mutations in the *pncA* gene have been acquired elsewhere or that individual patients had non-programmatic access to this drug.

Compensatory mutations can be a major factor in restoring the fitness reduction of strains due to drug-resistance-conferring mutations. Compensation for rifampicin resistance has been shown to be associated with mutations in *rpoA*, *rpoC*, and the non-hotspot region of the *rpoB* gene.[@b29-idr-11-2219] Our analysis detected mutations in the *rpoC* gene and outside the rifampicin-resistance-determining region, with four mutations (one in MDR-MTBC strain and three in non-MDR-MTBC strains) found in the *rpoA* gene. Altogether, 12 and 26 non-synonymous SNPs were detected in the *rpoC* gene and non-hotspot *rpoB* region, respectively. The *rpoC* mutation was more common in strains with an *rpoB* gene S450L mutation, in concordance with a recent study.[@b30-idr-11-2219] The rate of probable compensatory mutations found in MDR-MTBC isolates was relatively high (66.2%) compared to previous studies from other parts of the world (27--66%).[@b29-idr-11-2219],[@b30-idr-11-2219]

A larger scale population-based research is, of course, required in the near future through employing WGS to better understand the nature and route of MTB transmission in Saudi Arabia. Although the WGS technique is powerful, lack of accessibility to other demographic and medical indicators has prevented us from epidemiologically tracing the transmission chains in individual clusters. Due to the restrictions of the study design and time frame, we could possibly have missed MDR-MTBC isolates. To conclude, for the first time our results showed that Saudi Arabia is indeed suffering from ongoing MDR-MTBC transmissions indicated by high cluster rates and identical resistance-conferring mutations. As such, effective interruption of transmission chains requires improved TB surveillance, diagnosis, and treatment. In addition, incorporating WGS into the routine TB-management plan might be a crucial step in the future in Saudi Arabia. It facilitates an accurate diagnosis, optimized case management, and a detailed estimation of ongoing transmission dynamics, which is especially important in settings with high immigration and mobility rates.
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![Phylogeny of 71 MDR and 134 non-MDR-MTBC strains from Saudi Arabia.\
**Notes:** Maximum likelihood phylogeny of 205 isolates with annotated genomic MDR-MTBC clusters using 21,745 variable genome positions and 1,000 bootstrap resamples. Main MTBC lineages are annotated.\
**Abbreviations:** MDR, multidrug-resistant; MTBC, *Mycobacterium tuberculosis* complex; *M. bovis*, *Mycobacterium bovis*; CAS, Central Asian.](idr-11-2219Fig1){#f1-idr-11-2219}

###### 

Demographic and clinical summary of study subjects

  Parameters             n/% (N=205)   MDR, n/% (N=71)   Non-MDR, n/% (N=134)   OR (95% CI)            *P*-value
  ---------------------- ------------- ----------------- ---------------------- ---------------------- -----------
                                                                                                       
  Gender                                                                                               
  Male                   129 (62.9)    48 (67.6)         81 (60.4)              REF                    
  Female                 76 (37.1)     23 (32.4)         53 (39.6)              1.365 (0.745--2.502)   0.313
  Age group (years)                                                                                    
  \<15                   9 (4.4)       3 (4.2)           6 (4.5)                REF                    
  16--29                 66 (32.2)     19 (26.8)         47 (35.1)              1.236 (0.280--5.459)   0.779
  30--45                 76 (37.1)     24 (33.8)         52 (38.8)              1.083 (0.249--4.701)   0.914
  46--59                 33 (16.1)     17 (23.9)         16 (11.9)              0.470 (0.100--2.206)   0.338
  \>60                   21 (10.2)     8 (11.3)          13 (9.3)               0.812 (0.157--4.197)   0.805
  Nationality                                                                                          
  Saudi                  109 (53.2)    40 (56.3)         69 (51.5)              REF                    
  Non-Saudi              96 (46.8)     31 (43.7)         65 (48.5)              1.215 (0.681--2.168)   0.508
  -Indian subcontinent   36 (37.5)     11 (15.5)         25 (18.6)              1.317 (0.587--2.959)   0.504
  -African               29 (30.2)     12 (16.9)         17 (12.7)              0.821 (0.356--1.893)   0.644
  -Southeast Asian       20 (20.8)     6 (8.5)           14 (10.4)              1.352 (0.482--3.799)   0.566
  -Middle Eastern        11 (11.4)     2 (2.8)           9 (6.7)                2.609 (0.536--12.67)   0.234
  Residential province                                                                                 
  South                  18 (8.9)      5 (7.1)           13 (9.7)               REF                    
  West                   70 (34.1)     24 (33.8)         46 (34.3)              0.737 (0.235--2.312)   0.601
  East                   48 (23.4)     17 (23.9)         31 (23.1)              0.701 (0.213--2.303)   0.558
  Central                56 (27.3)     19 (26.8)         37 (27.6)              0.749 (0.232--2.414)   0.628
  North                  13 (6.3)      6 (8.4)           7 (5.2)                0.448 (0.100--2.013)   0.295
  Previous treatment                                                                                   
  Yes                    66 (32.2)     23 (32.4)         43 (32.1)              REF                    
  No                     139 (67.8)    48 (67.6)         91 (67.9)              1.014 (0.548--1.876)   0.964
  Positive AFB smear                                                                                   
  Yes                    148 (72.2)    62 (87.3)         86 (64.2)              REF                    
  No                     57 (27.8)     9 (12.7)          48 (35.8)              3.845 (1.756--8.415)   0.001
  Site of infection                                                                                    
  Pulmonary              181 (88.3)    67 (94.4)         114 (85.1)             REF                    
  Extra-pulmonary        24 (11.7)     4 (5.6)           20 (14.9)              2.938 (0.963--8.962)   0.058
  Treatment outcome                                                                                    
  Completed              81 (39.5)     21 (29.6)         60 (44.8)              REF                    
  Failed                 12 (5.8)      9 (12.6)          3 (2.2)                0.116 (0.028--0.472)   0.002
  Deported               9 (4.4)       7 (9.9)           2 (1.5)                0.100 (0.019--0.519)   0.006
  Died                   11 (5.4)      7 (9.9)           4 (3.0)                0.200 (0.053--0.752)   0.017
  Unknown                92 (44.9)     27 (38.0)         65 (48.5)              0.842 (0.431--1.645)   0.616

**Notes:** Indian subcontinent -- Afghanistan, India, Pakistan, Bangladesh, Nepal, and Myanmar; African -- Somalia, Sudan, Nigeria, Eritrea, Ethiopia, and Egypt; Middle Eastern -- Yemen and Syria; South East Asian -- Philippines and Indonesia. Provincial cities: South -- Jizan and Asir; West --Jeddah, Baha, Taif, and Medina; East -- Dammam; Central -- Riyadh; North -- Hail. Unknown: After diagnosis, the patient's follow-up was lost from the records.

**Abbreviations:** AFB, acid-fast bacilli; MDR, multidrug-resistant; *M. bovis*, *Mycobacterium bovis*; REF, reference.

###### 

Major phylogenetic lineages and sub-lineages classified by whole genome sequencing approach

  Phylogenetic lineages   n/% (N=205)   Clustered isolate/rate (N=98)   MDR, n/% (N=71)   Non-MDR, n/% (N=134)   95% CI                  *P*-value
  ----------------------- ------------- ------------------------------- ----------------- ---------------------- ----------------------- -----------
                                                                                                                                         
  Lineage 1               32 (15.6)                                     10 (14.1)         22 (16.4)              REF                     
  Lineage 2               16 (7.8)                                      12 (16.9)         4 (2.9)                0.151 (0.039--0.588)    0.006
  Lineage 3               43 (20.9)                                     17 (23.9)         26 (19.4)              0.695 (0.264--1.825)    0.460
  Lineage 4               113 (55.1)                                    32 (45.1)         81 (60.4)              1.150 (0.490--2.697)    0.747
  Sub-lineages                                                                                                                           
  3 Delhi-CAS             33 (16.1)     12 (12.2)                       11 (15.5)         22 (16.4)              REF                     
  4.2.2 Euro-American     26 (12.7)     15 (15.4)                       13 (18.3)         13 (9.7)               0.500 (0.174--1.437)    0.198
  1.1.2 EAI               20 (9.7)      12 (12.2)                       10 (14.1)         10 (7.5)               0.500 (0.160--1.558)    0.232
  2.2.1 Beijing           14 (6.8)      7 (7.1)                         9 (12.7)          5 (3.7)                0.277 (0.075--1.030)    0.055
  4.1.2.1 Haarlem         13 (6.3)      9 (9.2)                         1 (1.4)           12 (8.9)               6.00 (0.689--52.26)     0.104
  4.6.2.2 Cameroon        13 (6.3)      9 (9.2)                         7 (9.8)           6 (4.5)                0.429 (0.115--1.586)    0.204
  4.4.1.1 S-type          8 (3.9)       5 (5.1)                         3 (4.2)           5 (3.7)                0.833 (0.167--4.143)    0.823
  4.8 Euro-American       8 (3.9)       3 (3.1)                         3 (4.2)           5 (3.7)                0.833 (0.167--4.143)    0.823
  4.3.3 LAM               7 (3.4)       2 (2.0)                         3 (4.2)           4 (2.9)                0.667 (0.126--3.515)    0.632
  1.2.1 EAI Manila        5 (2.4)       --                              1 (1.4)           4 (2.9)                2.000 (0.199--20.104)   0.556
  3.1.2.1 Delhi-CAS       5 (2.4)       4 (4.1)                         2 (2.8)           3 (2.2)                0.750 (0.108--5.167)    0.770
  4 Euro-American         4 (2.0)       --                              1 (1.4)           3 (2.2)                1.50 (0.139--16.144)    0.738
  3.1.1 Delhi-CAS         2 (1.0)       --                              1 (1.4)           1 (0.7)                0.500 (0.028--8.772)    0.635
  1.2.2 EAI               3 (1.5)       --                                                3 (2.2)                --                      --
  4.5 Euro-American       6 (2.9)       2 (2.0)                                           6 (4.5)                --                      --
  1.1.3 EAI               4 (2.0)       --                                                4 (2.9)                --                      --
  4.6 Euro-American       4 (2.0)       3 (3.1)                                           4 (2.9)                --                      --
  3.1.2 Delhi-CAS         3 (1.5)       3 (3.1)                         3 (4.2)                                  --                      --
  4.1 Euro-American       3 (1.5)       3 (3.1)                                           3 (2.2)                --                      --
  4.1.1.3 X-type          3 (1.5)       --                                                3 (2.2)                --                      --
  4.2.2.1 TUR             3 (1.5)       3 (3.1)                                           3 (2.2)                --                      --
  4.7 Euro-American       3 (1.5)       2 (2.0)                                           3 (2.2)                --                      --
  4.2.1 Ural              2 (1.0)       --                                                2 (1.5)                --                      --
  4.3.4.2.1 LAM           2 (1.0)       2 (2.0)                                           2 (1.5)                --                      --
  4.4 Euro-American       2 (1.0)       2 (2.0)                                           2 (1.5)                --                      --
  2.2.1.1 Beijing         1 (0.5)       --                              1 (1.4)                                  --                      --
  2.2.2 Beijing           1 (0.5)       --                              1 (1.4)                                  --                      --
  4.3 LAM                 1 (0.5)       --                                                1 (0.7)                --                      --
  4.3.1 LAM               1 (0.5)       --                                                1 (0.7)                --                      --
  4.3.2 LAM               1 (0.5)       --                                                1 (0.7)                --                      --
  4.3.4.1 LAM             1 (0.5)       --                              1 (1.4)                                  --                      --
  4.3.4.2 LAM             1 (0.5)       --                                                1 (0.7)                --                      --
  4.6.1.1 Uganda          1 (0.5)       --                                                1 (0.7)                --                      --
  *M. bovis*              1 (0.5)       --                                                1 (0.7)                --                      --

**Abbreviations:** MDR, multidrug-resistant; *M. bovis*, *Mycobacterium bovis*; EAI, East African Indian; LAM, Latin American Mediterranean; TUR, Turkish.

###### 

Characteristics of 14 MDR-TB genomic clusters

  Clusters     No of isolates   Lineage         Gender             Age, (mean)   Nationality                City of residence        Treatment outcome                          Pza (N/%)   Emb (N/%)   Str (N/%)   Flq (N/%)   Compensatory mutations N (%)   XDR/Pre XDR (N)
  ------------ ---------------- --------------- ------------------ ------------- -------------------------- ------------------------ ------------------------------------------ ----------- ----------- ----------- ----------- ------------------------------ -----------------
                                                                                                                                                                                                                                                               
  Cluster-6    **4**            **Delhi-CAS**   **M (3), F (1)**   **49**        **Saudi**                  **Dammam**               **Completed (1), Unknown (3)**             **--**      4 (100)     4 (100)                 **--**                         **--**
  Cluster-7    4                EAI             M (3), F (1)       43            Saudi (3), Non-Saudi (1)   Taif (3), Jeddah (1)     Completed (1), Failed (2), died (1)        3 (75)      3 (75)      4 (100)                 --                             --
  Cluster-8    4                Euro-American   M                  42.2          Non Saudi (3), Saudi (1)   Jizan (3), Jeddah (1).   Deported (2), Unknown (2)                  4 (100)     3 (75)      --                      *rpoC*: 4 (100);               --
  Cluster-9    6                Cameroon        M (4), F (2)       35.3          Saudi (5), Non Saudi (1)   Taif (5), Medina (1)     Completed (2), Unknown (3) Died (1)        6 (100)     5 (83.3)    6 (100)                 *rpoB:6 (100)*                 --
  Cluster-11   4                Delhi-CAS       M (3), F (1)       60.5          Saudi (3), Non-Saudi (1)   Taif(3), Jeddah(1)       Deported (1), completed (2), Unknown (1)   --          --          4 (100)                 *rpoB:4 (100)*                 --
  Cluster-12   4                EAI             F                  54.7          Saudi                      Dammam                   Completed (2) Died (2)                     --          4 (100)     --                      *rpoC*:4 (100)                 --
  Cluster-13   5                Beijing         F (3), M (2)       36.4          Saudi (3), Non-Saudi (2)   Riyadh                   Failed (3), completed (1) Unknown (1)      5 (100)     5 (100)     5 (100)                 *rpoB:5 (100)*                 --
  Cluster-14   3                Delhi-CAS       M                  40.7          Saudi (2), Non-Saudi (1)   Riyadh                   Unknown (2), Died (1)                      --          3 (100)     3 (100)                 --                             --
  Cluster-15   3                Euro American   M                  27.3          Non-Saudi                  Riyadh                   Unknown (3)                                3 (100)     3 (100)     3 (100)                 --                             --
  Cluster-19   3                S-type          F                  19.3          Saudi (2), Non-Saudi (1)   Taif                     Completed (1), unknown (2)                 3 (100)     3 (100)     --                      --                             --
  Cluster-27   2                Euro-American   M                  31            Saudi                      Dammam                   Completed (1) Failed (1)                   2 (100)     2 (100)     --                      *rpoB:2 (100)*                 --
  Cluster-30   2                Euro-American   M                  35            Saudi                      Hail                     Completed (1), Failed (1)                  --          --          --                      *rpoB:2 (100)*                 --
  Cluster-31   2                Delhi-CAS       M                  36.5          Saudi (1), Non-Saudi (1)   Hail                     Deported (1), completed (1)                2 (100)     2 (100)     --          2 (100)     *rpoC*:2 (100)                 *2*
  Cluster-10   2                Euro-American   M/F                23.5          Saudi                      Taif                     Completed (1) Unknown (1)                  --          2 (100)     2 (100)     --          --                             --

**Notes:** Treatment regiments have been given to patients; no culture conversion was documented (failed), with confirmed culture conversion (completed).

**Abbreviation:** EMB, ethambutol; Flq, fluoroquinolone; PZA, pyrazinamide; Str, streptomycin; XDR, extensively resistant.

###### 

Demographic and clinical risk

  Parameters             Total (MDR)   Clustered; N=48 (n/%)   Non-clustered; N=23 (n/%)   OR (95% CI)             *P*-value
  ---------------------- ------------- ----------------------- --------------------------- ----------------------- -----------
                                                                                                                   
  Gender                                                                                                           
  Male                   50            33 (68.7)               17 (73.9)                   REF                     
  Female                 21            15 (31.3)               6 (26.1)                    0.776 (0.255--2.363)    0.597
  Age group (years)                                                                                                
  \<15                   3             2 (4.2)                 1 (4.3)                     REF                     
  16--29                 17            11 (22.9)               6 (26.1)                    0.545 (0.028--10.368)   0.687
  30--45                 24            14 (29.2)               10 (43.5)                   1.428 (0.113--18.00)    0.782
  46--59                 19            17 (35.4)               2 (8.7)                     0.235 (0.014--3.917)    0.313
  \>60                   8             4 (8.3)                 4 (17.4)                    2.00 (0.125--31.97)     0.624
  Nationality                                                                                                      
  Saudi                  43            30 (62.5)               13 (56.5)                   REF                     
  Non-Saudi              28            18 (37.5)               10 (43.5)                   1.281 (0.467--3.521)    0.629
  residential province                                                                                             
  South                  5             3 (6.2)                 2 (8.7)                     REF                     
  West                   25            19 (39.6)               6 (26.1)                    0.474 (0.063--3.538)    0.467
  East                   17            12 (25.0)               5 (21.7)                    0.625 (0.079--4.958)    0.656
  Central                18            10 (20.8)               8 (34.8)                    1.2 (0.159--90.131)     0.859
  North                  6             4 (8.3)                 2 (8.7)                     0.75 (0.064--8.833)     0.819
  Previous treatment                                                                                               
  Yes                    22            4 (8.3)                 18 (90.0)                   REF                     
  No                     49            44 (91.7)               5 (21.7)                    0.025 (0.006--0.105)    \<0.001
  Positive AFB smear                                                                                               
  Yes                    62            41 (85.4)               21 (91.3)                   REF                     
  No                     9             7 (14.6)                2 (8.7)                     0.557 (0.106--2.925)    0.490
  Treatment outcome                                                                                                
  Completed              21            14 (29.2)               7 (30.4)                    REF                     
  Failed                 8             7 (14.6)                1 (4.3)                     0.285 (0.029--2.802)    0.282
  Deported               7             4 (8.3)                 3 (13.1)                    1.50 (0.260--8.635)     0.649
  Died                   6             5 (10.4)                1 (4.3)                     0.400 (0.039--4.114)    0.441
  Unknown                29            18 (37.5)               11 (47.9)                   1.222 (0.377--3.967)    0.738
  Strain lineage                                                                                                   
  Lineage 1              10            8 (16.7)                2 (8.7)                     REF                     
  Lineage 2              12            5 (10.4)                7 (30.4)                    5.6 (0.814--38.51)      0.079
  Lineage 3              17            13 (27.1)               4 (17.4)                    1.231 (0.182--8.33)     0.831
  Lineage 4              32            22 (45.8)               10 (43.5)                   1.818 (0.325--10.157)   0.496

**Abbreviations:** AFB, acid-fast bacilli; MDR, multidrug-resistant.

[^1]: These authors contributed equally to this work
